• Share
  • Email
  • Embed
  • Like
  • Private Content
IBM Technology Day 2013 Keynote B. Dubuis
 

IBM Technology Day 2013 Keynote B. Dubuis

on

  • 520 views

 

Statistics

Views

Total Views
520
Views on SlideShare
520
Embed Views
0

Actions

Likes
0
Downloads
24
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    IBM Technology Day 2013 Keynote B. Dubuis IBM Technology Day 2013 Keynote B. Dubuis Presentation Transcript

    • 1IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Click to edit Master title style© 2013 Benoit Dubuis© 2013 IBM CorporationMedical revolution andnew technologiesDr. Benoit Dubuis,Directeur Eclosion, Président BioAlps11 juin 2013
    • MEDTECH“Medical revolution and new technologies”The challengesTowards an integrated health systemOur contributionInnovation: The New Currency ofCompetition
    • MEDTECH“Medical revolution and new technologies”The challengesTowards an integrated health systemOur contributionInnovation: The New Currency ofCompetition
    • Crossing Visions13.06.2013 | 4PRINCIPAUX DEFISDANS LE DOMAINE DE LA SANTEDEFIS SCIENTIFIQUESAUTRES DEFISDémographieCoûtsAccèsAdoption lente de l’innovationUtilisation inefficace de l’information…
    • Crossing Visions13.06.2013 | 5CAUSE DEMORTALITETOUTES LESCAUSES100%Cardiopathieischémique13%MaladiesCardio-vasculaire29% MaladiesInfectieuses etparasite23%Cancers12%Maladiesvasculairescérébrales9%Maladiesrespiratoires7%SIDA4.87%
    • Crossing Visions13.06.2013 | 6PDEMOGRAPHIE:NOUS VIVONS PLUSLONGTEMPS908070605040Espérancedevieàlanaissance1900 1950 2000CH: 77CH: 82CH: 77CH: 82Age 60 – 2 MiaAge 80 – 380 MioAge 100 – 2 Mio2050Point de référence:Espérance de vie durant l’empire Romain était de ~30 ans
    • Crossing Visions13.06.2013 | 7DEMOGRAPHIE:NOUS VIVONS EN MEILLEURESANTEAncien modèleEn bonne santé MaladeMaladeModèle comprimant la morbiditéEn bonne santéAnnées de viegagnéesMaladeModèle actuelEn bonne santé
    • Crossing Visions13.06.2013 | 9LA CHARGEDES MALADIES CHRONIQUESPrès de la moitié d’entrenous aura un état chroniqued’ici 2030 :DiabètesHypertensionArthriteAthérosclérosesAccident vasculaire cérébraleCancerObésitéHyperlipidémieMaladie NeurodégénérativeMaladie Dégénérative ArticulaireMaladie pulmonaire obstructiveEtc. Dépense dans ledomaine de la santépour une personne avecmaladie chroniqueDépense dans le domainede la santé pour unepersonne sans maladiechroniqueEtats chroniquesreprésenteront près83% des coûts desanté
    • Crossing Visions13.06.2013 | 10COÛT DE LASANTE
    • Crossing Visions13.06.2013 | 11LES NOUVELLESPISTESMédecine 3PPharmacogénomiqueBioconvergenceMédecine TranslationnelleTélémédecine
    • Crossing Visions13.06.2013 | 12DE LA MEDECINE « PRÊT-A PORTER »àLA MEDECINE PERSONALISEEGénomiqueProtéomique
    • Crossing Visions13.06.2013 | 13PREVENTIVEPREDICTIVEPERSONNALISEEModèle comprimant la morbiditéEn bonne santéAnnées de viegagnée MaladePersonnaliséMortalitéPréventifMorbiditéPrédictif
    • Crossing Visions13.06.2013 | 14VERS UN SYSTEME DESANTE INTEGRERx2009
    • 15IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Click to edit Master title styleMEDTECH“Medical revolution and new technologies”The challengesTowards an integrated health systemOur contributionInnovation: The New Currency ofCompetition
    • Crossing Visions13.06.2013 | 16LA FORCEDURESEAUCENTRESMEDICAUXOUTILS DERECHERCHEINDUSTRIESSTART-UPCENTRESACADEMIQUES
    • Crossing Visions13.06.2013 | 17INNOVATION etINTERDISCIPLINARITE
    • Crossing Visions13.06.2013 | 18INNOVATION etINTERDISCIPLINARITEBiotechnologie,Systèmes BiologiquesetBiologie SynthétiqueNanotechnologieScience des MatériauxetIngénierie deMiniaturisationInformatique depointeetWIRELESS
    • 19IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Interdisciplinarity (science driven)
    • 20IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Interdisciplinarity (science driven)
    • 21IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Click to edit Master title styleMEDTECH“Medical revolution and new technologies”The challengesTowards an integrated health systemOur contributionInnovation: The New Currency ofCompetition
    • 22IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Micro /nanotechclusterBio-clusterA unique hubfor Medtech/Biotech R&D in Europe
    • Crossing Visions13.06.2013 | 23INSTITUTIONSR&D DE CLASSEINTERNATIONALEGénérer des connaissancesCréer des opportunités
    • Crossing Visions13.06.2013 | 24QUALITE DESRECHERCHESNombre de publication par 1000 habitantsdans tous les domaines de connaissances et dans le domaine des Sciences de la vie
    • 25IBM Technology Day 2013, Keynote B. Dubuis11.6.2013evolutionary developmental biologyElectronic health recordACCES AUX TECHNOLOGIES,OUTILS ET CONNAISSANCES
    • Crossing Visions13.06.2013 | 26De l’idée au produitCréer de la valeur économique et desemplois
    • Crossing Visions13.06.2013 | 27SARAH MARQUISCONNECTEECoupure de journalSarah Marquis…
    • Crossing Visions13.06.2013 | 28IMPACT SUR LAPRISE EN CHARGE020406080100Chf 13’800Chf 5’900DIABETE:COÛT TOTAL vs COÛT DES MEDICAMENTS
    • Crossing Visions13.06.2013 | 29SYSTEME DESANTE INTEGRE020406080100Chf 13’800Chf 5’900PrédictionPersonnalisationSuivi àdistanced’unPatient
    • 30IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Remote Patient MonitoringWorldwide Mobile NetworkCarrierMoving data from body toinstrument (Programmer/PatientCompanion) to wireless carrierworldwide.Intimate Body NetworkDevice to Device within the bodyPersonal Body NetworkMove data from device toprogrammer or device to deviceDistance: inches to several feet
    • 31IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Personalized MedicineSmart SensingIntelligentInformationManagementEffectiveInterfacesPutting the patient at the center of their health system
    • 32IBM Technology Day 2013, Keynote B. Dubuis11.6.2013CSEM’sTechnology ProgrmsMEMSUltra-low-power integratedsystemsSystemsSurface engineeringNon-invasive wearable sensorsPersonal biosensorsEnvironmental sensorsNew data streams + machinelearning = “New vital signs”Smart sensing
    • 33IBM Technology Day 2013, Keynote B. Dubuis11.6.2013CSEM: Human vital signs MultiparameterSensingSpO2 / CBTNIBPECGrespirationHR / HRV CO2 / O2
    • 34IBM Technology Day 2013, Keynote B. Dubuis11.6.2013GeophysicalExperimentWalkingSittingDonningSittingWalkingDoffingTakingsampleFall• CBT• HR• BR• SpO2• 3D-ACCCSEM : LTMS clinical study sample
    • 35IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Intelligent Information ManagementLongitudinal dataPersonal baselineDetect trends & deviations from normPersonal health recordsPrivacySharingAnonymous aggregationPatient-centered decision support
    • 36IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Effective InterfacesMultimodalGUI, touch, gesture, speech, …MobilePortable, networked, wearableIntuitiveEasy to learn, use, maintainAdaptiveProactiveSource: Henry Kautz Department of Computer Science, Rochester University
    • 37IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Ten Targets for Wireless MedicineAlzheimer’s 5M Vital signs, location, activity, balanceAsthma 23M RR, FEV1, Air quality, oximetry, pollencountBreast Cancer 3M Ultrasound self-exam  WebCOPD* 10M RR, FEV1, Air quality, oximetryDepression 21M Med Compliance, Activity, CommunicationDiabetes 24M Glucose, Hemoglobin A1CHeart Failure 5M Cardiac pressures, weight, BP, fluid statusHypertension 74M Continuous BP, Med complianceObesity 80M Smart scales, Glucose, Caloric in/out,ActivitySleep Disorders 40M Sleep phases, quality, apnea, vital signsDisease No. Affected Wireless SolutionsDisease Wireless SolutionsNo. AffectedDisease Wireless Solutions* Chronic obstructive pulmonary diseaseSource: Burrill
    • 38IBM Technology Day 2013, Keynote B. Dubuis11.6.2013The shift to patient-empowering,information-leveraging technologies“PI” (patient-empowering and information-leveraging) technologies
    • 39IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Source: George PosteAccess,cost andqualityof careMolecularandpersonalizedmedicineProficientuse ofinformation(e.health)Link between Genomic and physiology
    • 40IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Biocorpora –Drugdesigntech SACollaborative Drug DiscoverySource:Dr.CédricMerlot,DrugDesignTechInformation matters – Data lifecycle
    • 41IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Sharing informationHuge amount of data produced, but not sharedProduced by HT technologies: screening, -omicsStored in data silos, only useable by specialistsNeed for one-stop-shop for all data for everybodyProvide a single point-of-entry to all project dataExplain raw data to non-specialists scientistsShare data across multi disciplinary research teamsEnable re-analysis, reuse dataCombine information from multiple sourcesDrill down from summarized data to raw dataSource:Dr.CédricMerlot,DrugDesignTech
    • 42IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Collaborative Drug Discoverypublicationmolecules High troughputproject leaders data analysis labsin-contextreportingBiocorporaproposals CROSource:Dr.CédricMerlot,DrugDesignTech
    • 43IBM Technology Day 2013, Keynote B. Dubuis11.6.2013The application of various omic-technologies isleading to the generation of vast amounts of dataSystems Biology studies assemblies of interacting biomolecularcomponents at multiple levels of biological abstraction.The current challenge is to develop new computational tools andanalytical procedures that allow the integration of these variousdatasets
    • 44IBM Technology Day 2013, Keynote B. Dubuis11.6.2013- omics Data ManagementMicroarray Flow cytometry NMR Mass spectrometryanalysisproject leaders data analysis labsin-contextreportingBiocorporaSource:Dr.CédricMerlot,DrugDesignTech
    • 45IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Megaclust: SIB, Vital-IT & GenebioEnabling flow cytometry data analysisRethinking EnablingDataacquisitionResult Analysis anddecision makingIdentification of cell typesLeveraging the power of flow cytometry in clinical trials is agreat challenge due to the size and complexity of the datagenerated.MegaClust thoroughly and accurately identifies the differentcell types present in the datasetSource:megaclust.vital-it.ch
    • 46IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Megaclust: SIB, Vital-IP & GenebioEnabling flow cytometry data analysisMegaClust is an integrated service for the analysis of large andcomplex flow cytometry datasets- Proprietary algorithm- Optimized for massive parallelization- Deployed on 256 processors- MultidisciplinaryexpertiseSource:megaclust.vital-it.ch
    • 47IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Megaclust: Example of identification of AMLtreated patients among 50 individualsMegaClust5 markersper sample...50individuals1.5 M cells (30 K cells * 50 ) and 5 dimensions ( )AML: acute myeloid leukemiaSource:megaclust.vital-it.ch
    • 48IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Megaclust: Each individual has unique amountsof each identified cell types (unique fingerprint)50 individuals16identifiedcelltypesEach column represents a patient specific cellular fingerprintA5A174A49C62C287C330C84C201A219C200C321C35C184C206C213C77C241C86C356C315C229C41C182C320C85C317C272C282C277C178C80C91C129C254C343C251C193cellularfingerprintSource:megaclust.vital-it.ch
    • 49IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Megaclust: Fingerprints have the power tostratify individuals (separate controls from AML)AMLControl- No a priori assumptions →unrestricted analysis- No human bias- Reproducible- Handles very large data sets- FastSource:megaclust.vital-it.ch
    • 50IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Megaclustenables stratification and thereforeprovides key insight at each phase of the drugdevelopment pipelinetoxicity/effectiveness assessmentStratificationdesign of focused patient groupmarkers selectionresponders characterizationadverse effectsphase1 phase 2 phase3preclinicalanimalshealthyvolunteerssmall group of patients large group of patientsSource:megaclust.vital-it.ch
    • 51IBM Technology Day 2013, Keynote B. Dubuis11.6.2013IBM BlueGene/L
    • IBM Systems & Technology GroupEPFL / IBM Confidential | 6/13/201352EPFL’s Brain & Mind Institute: Application Needs NeuroInformatics• 10++ different databases, ~ 100TB of Storage required• 1000 to 10’000 Cells structure information NeuroSimulation• BioChemical Networks• Molecular Interactions underlying Synaptic Processes• Microcircuits NeuroVisualization• Synaptic Structure• Neuronal Structure• Microcircuit Structure
    • 53IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Praesalio – Drugdesigntech SAPredictive ToxicologyLack of safety is a major cause of attritionRaised during clinical phases, incl. Phase IVLoss of all investmentsReduces therapeutic window (lack of efficacy)Identify and fix potential issues in drug discoveryStructural modifications are still allowedDeliver fully characterized compoundsNeed for focused, fast evaluation of liabilitiesComputer predictions to focus on relevant experiments1000’s of endpoints evaluated fast and at low costSource:Dr.CédricMerlot,DrugDesignTech
    • 54IBM Technology Day 2013, Keynote B. Dubuis11.6.2013From data to informationActivity DB ModelsProjectinformationCrunching Predictions1M+ structures10M+ activities3000 models6Tb storage1 answerwhat are the liability in mycompound ?Source:Dr.CédricMerlot,DrugDesignTech
    • 55IBM Technology Day 2013, Keynote B. Dubuis11.6.2013Click to edit Master title styleMEDTECH“Medical revolution and new technologies”The challengesTowards an integrated health systemOur contributionInnovation: The New Currency ofCompetition
    • Crossing Visions13.06.2013 | 56COMMUNAUTEINDUSTRIELLE
    • Crossing Visions13.06.2013 | 57CHAMPION DU MONDEDE LA CROISSANCEVitesse moyenne de croissance annuelle 95-00, 00-06Source: BAK, Basel Economics
    • 58IBM Technology Day 2013, Keynote B. Dubuis11.6.2013A Successfull biocluster
    • UNRESEAUD’EXCELLENCE…et tant d’autres!
    • © 2013 IBM CorporationFind the slides on:www.republic-of-innovation.chDr. Benoit DubuisFondation Eclosion14, Ch. Des AulxCH-1228 Plan-les-OuatesTel 022 880 10 10bd@eclosion.com